Buspirone

Generic Name: Buspirone

Brand Names: Buspar

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₁N_₅O_₂

CAS Number: 36505-84-7

Unique Ingredient Identifier: TK65WKS8HL

Background: Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspiro...

Indication: Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.

Associated Conditions: Anxiety Disorders, Depression

Associated Therapies: -

Clinical Trials

Evaluating Buspirone to Treat Opioid Withdrawal

Phase 2

Recruiting

Conditions: Anxiety
Opioid Withdrawal
Opioid Craving
Opioid Use Disorder

Interventions: Drug: Buspirone
Drug: Placebo
Drug: Lofexidine

First Posted Date: 2022-08-23

Last Posted Date: 2023-12-14

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 100

Registration Number: NCT05511909

Locations: 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Phase 3

Completed

Conditions: Autonomic Dysfunction
Vertigo

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2022-06-24

Last Posted Date: 2022-06-24

Lead Sponsor: Valenta Pharm JSC

Target Recruit Count: 268

Registration Number: NCT05430217

Locations: 🇷🇺
Limited Liability Company "MK-Med", Saint Petersburg, Russian Federation
🇷🇺
Limited Liability Company "MART", Saint Petersburg, Russian Federation
🇷🇺
Saint Petersburg State Budgetary Institution of Healthcare "City Hospital No. 40 of Kurortny District", Saint Petersburg, Russian Federation

and more 5 locations

Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial

Phase 1

Completed

Conditions: Dyspepsia

Interventions: Drug: Placebo
Drug: Buspirone
Drug: Prucalopride

First Posted Date: 2022-05-17

Last Posted Date: 2022-05-17

Lead Sponsor: Universidade de Passo Fundo

Target Recruit Count: 1

Registration Number: NCT05377619

Locations: 🇧🇷
University of Passo Fundo, Passo Fundo, RS, Brazil

Improving Ventilatory Capacity in Those With Chronic High Level SCI

Phase 2

Recruiting

Conditions: Spinal Cord Injuries

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2021-09-13

Last Posted Date: 2023-02-09

Lead Sponsor: Spaulding Rehabilitation Hospital

Target Recruit Count: 30

Registration Number: NCT05041322

Locations: 🇺🇸
Spaulding Hospital Cambridge, Cambridge, Massachusetts, United States

Buspirone Treatment of Anxiety in Williams Syndrome

Phase 4

Completed

Conditions: Anxiety
Williams Syndrome

Interventions: Drug: Buspirone

First Posted Date: 2021-03-19

Last Posted Date: 2024-12-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT04807517

Locations: 🇺🇸
Lurie Center for Autism, Lexington, Massachusetts, United States

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

Phase 4

Recruiting

Conditions: Depression
Brain Injuries, Traumatic

Interventions: Drug: Buspirone
Drug: Mealatonin

First Posted Date: 2020-05-22

Last Posted Date: 2024-04-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT04400266

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Home Base Program, Charlestown, Massachusetts, United States

Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers

Not Applicable

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2020-04-20

Last Posted Date: 2020-04-20

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 10

Registration Number: NCT04352686

Transformation of Paralysis to Stepping

Early Phase 1

Recruiting

Conditions: Spinal Cord Injuries

Interventions: Drug: Buspirone
Device: Non-invasive Spinal Cord Stimulation
Device: Gravity Neutral Device
Device: Ekso Bionics Exoskeleton
Device: Body Weight Supported Treadmill Training
Device: Rolling Walker

First Posted Date: 2019-09-26

Last Posted Date: 2024-02-28

Lead Sponsor: University of Louisville

Target Recruit Count: 15

Registration Number: NCT04105114

Locations: 🇺🇸
Frazier Rehabilitation and Neuroscience Institute, Louisville, Kentucky, United States

Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES

Phase 1

Completed

Conditions: Spinal Cord Injuries
Drug Effect

Interventions: Drug: Placebo oral tablet
Drug: Levodopa-Carbidopa
Drug: Buspirone + Levodopa-Carbidopa
Drug: Buspirone

First Posted Date: 2019-08-12

Last Posted Date: 2023-10-05

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 3

Registration Number: NCT04052776

Locations: 🇨🇭
CHUV, Lausanne, Vaud, Switzerland

Buspirone for Early Satiety and Symptoms of Gastroparesis

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: Buspirone
Drug: Placebo

First Posted Date: 2018-07-16

Last Posted Date: 2023-06-15

Lead Sponsor: Johns Hopkins Bloomberg School of Public Health

Target Recruit Count: 96

Registration Number: NCT03587142

Locations: 🇺🇸
Texas Tech University Health Science Center, El Paso, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy